Lever
Lifestyle
- Regular moderate exercise
- Stress management
- Adequate hydration
Blutwerte · Marker
aPTT
Activated Partial Thromboplastin Time · PTT
Gerinnung
- Einheit:
- seconds
The aPTT test quantifies the time required for blood to clot via the intrinsic and common coagulation pathways.
Reference Ranges
Reference
22–38seconds
22
38
LowNormalHigh
Reference
Unit · secondsReference ranges may vary slightly based on local laboratory standards and methodologies.
Overview
Übersicht
Activated Partial Thromboplastin Time (aPTT) is a blood test that measures the time it takes for a clot to form in a blood sample after reagents are added. It specifically evaluates the intrinsic and common coagulation pathways, providing insights into the functionality of clotting factors such as VIII, IX, XI, and XII. Researchers have standardized the aPTT test to ensure consistent results across different laboratories by using a reference preparation of phospholipid material. Clinically, aPTT is crucial for diagnosing bleeding disorders, monitoring heparin therapy, and assessing the risk of thrombosis. Elevated aPTT values may indicate coagulation factor deficiencies, liver disease, or the presence of anticoagulants, while reduced values are less common but could suggest hypercoagulable states. In the context of athletic performance and biohacking, aPTT may not be directly relevant, but maintaining optimal coagulation function is essential for recovery and injury prevention. Researchers have found that factors such as exercise, diet, and hydration can influence coagulation parameters, indirectly affecting aPTT. Caveats include the influence of heparin therapy, which requires careful monitoring, and the variability introduced by different reagents and instruments used in testing. Time of day and fasting status generally do not affect aPTT, but acute illness or stress can alter results. Therefore, standardized testing conditions are recommended to ensure accurate interpretation.
Klinische Bedeutung
Elevated aPTT values can indicate coagulation factor deficiencies, liver disease, or anticoagulant presence. Reduced aPTT values are rare but may suggest hypercoagulable states.
Dynamics
Trend Interpretation
Rising Values
Progressively rising aPTT values suggest increased bleeding risk or anticoagulant effect. Re-test within 1-2 weeks if values are outside the therapeutic range.
Falling Values
Progressively falling aPTT values may indicate reduced anticoagulant effect or resolution of a coagulation disorder.
Re-test Interval
1-2 weeks if outside therapeutic range
Etiology
Causes — High & Low
Cause
Elevated Levels
- Coagulation factor deficiencies
- Liver disease
- Heparin therapy
- Antiphospholipid syndrome
- Vitamin K deficiency
Cause
Low Levels
- Hypercoagulable states
- Pregnancy
- Acute phase response
- Factor VIII elevation
Protocol
How to Optimize
Lever
Nutrition
- Balanced diet rich in vitamin K
- Avoid excessive alcohol consumption
Note:
Consult a healthcare provider before making significant changes, especially if on anticoagulant therapy.
Testing Guidelines
✓Fasting Not Required
✓Not Time-Sensitive
Testing Frequency
As needed for anticoagulant therapy monitoring or bleeding disorder evaluation.
Interfering Factors
- Heparin administration
- Lupus anticoagulant presence
- Improper sample handling
Open Research Questions
Current research suggests that the impact of reference interval sources on aPTT result classification, particularly in pediatric populations, remains understudied, with significant variability in out-of-reference-interval flagging rates. Emerging research directions include the development of predictive models for aPTT values in critically ill patients receiving heparin, yet clinical questions remain unanswered regarding the optimal management strategies for patients with prolonged aPTT and the influence of different reagents on test precision.
41 Research Publications
817
Total Citations
18
Human/RCT
2.6
Avg. Influence
2025
Latest
Sort
Filter
01Top
#01
Antifactor Xa levels versus activated partial thromboplastin time for monitoring unfractionated heparin.
ReviewInfluence5.0
229
Researchers examined the monitoring of unfractionated heparin (UFH) and found that the activated partial thromboplastin time (aPTT) has significant variability, leading to recommendations for antifactor Xa levels instead. The study indicated that this transition could provide more stable monitoring with fewer adjustments. The findings suggest that antifactor Xa may be a cost-effective alternative for UFH monitoring.
02Top
#02
Laboratory testing of anticoagulants: the present and the future.
ReviewInfluence6.0
111
This review provided an update on laboratory testing for anticoagulants, including activated partial thromboplastin time (aPTT). Researchers discussed the benefits and limitations of current tests and highlighted the need for proactive development of strategies for monitoring new anticoagulants, despite the ongoing use of traditional tests.
03Top
#03
Activated Partial Thromboplastin Time Monitoring of Unfractionated Heparin Therapy: Issues and Recommendations.
Marlar Richard A, et al. · Seminars in thrombosis and hemostasis · 2017
ReviewInfluence4.0
78
Researchers reviewed the challenges of monitoring unfractionated heparin therapy using aPTT. They highlighted the variability in aPTT results due to patient factors and reagent differences. The study provided recommendations for establishing a consistent therapeutic range for aPTT in various hospital settings.
Key findings
- 01Researchers observed that the APTT test is commonly used but only estimates heparin concentration.
- 02They noted that patient differences and test conditions can affect APTT results.
- 03The article suggests ways for laboratories to better establish heparin therapeutic ranges.
04
#04
Therapeutic monitoring of unfractionated heparin - trials and tribulations.
ReviewInfluence3.0
55
This study explored the challenges in therapeutic monitoring of unfractionated heparin (UFH), noting the variability in activated partial thromboplastin time (aPTT) results. Researchers found that while aPTT is widely used, its relevance to current laboratory practices is limited, and alternative monitoring methods may be more effective.
05
#05
Laboratory investigations for bleeding disorders.
ReviewInfluence3.0
48
Researchers explored the effectiveness of coagulation tests, including aPTT, in detecting bleeding disorders. They found that while these tests have high specificity, their sensitivity for clinically significant abnormalities is low. The study suggests that expanding testing panels may improve detection rates for bleeding disorders.
06
#06
Coagulation in Liver Disease.
Review
39
Researchers discussed the liver's role in hemostasis, noting that standard tests like aPTT and PT do not fully reflect coagulation status in liver disease. The study emphasized that these tests may not accurately predict bleeding or thrombosis risks in patients with liver failure.
07
#07
COVID-19-related laboratory coagulation findings.
Devreese Katrien M J · International journal of laboratory hematology · 2021
ReviewInfluence1.0
38
Researchers observed that COVID-19 patients exhibit significant coagulation abnormalities, including elevated activated partial thromboplastin time (aPTT). The study highlighted the role of hemostasis testing in diagnosing COVID-19 and noted that while aPTT is affected, it currently has no place in the management of the disease.
Key findings
- 01Researchers found that COVID-19 patients have a high prothrombotic status, increasing their risk of blood clots.
- 02Elevated D-dimer levels serve as a crucial marker for assessing thrombosis risk in these patients.
- 03Other coagulation parameters may indicate changes in blood clotting but are not yet standard for diagnosis or management.
08
#08
Evaluation of Antifactor-Xa Heparin Assay and Activated Partial Thromboplastin Time Values in Patients on Therapeutic Continuous Infusion Unfractionated Heparin Therapy.
HumanInfluence2.0
32
09
#09
Comparison of clinical outcomes using activated partial thromboplastin time versus antifactor-Xa for monitoring therapeutic unfractionated heparin: A systematic review and meta-analysis.
Meta-AnalysisInfluence2.0
28
10
#10
Unexpected, isolated activated partial thromboplastin time prolongation: A practical mini-review.
ReviewInfluence2.0
28
This mini-review addressed the interpretation of unexpected isolated prolonged aPTT. Researchers found that this condition can indicate various issues, including lupus anticoagulants or factor deficiencies. The study provided a diagnostic algorithm to help differentiate between these causes, emphasizing the importance of accurate diagnosis for effective management.
Clinical Trials (2)
2
Total Trials
172
Total Enrolled
Effects of Tourniquet Applied During Total Knee Replacement Surgery on Patient Hemodynamics and Blood Table
NCT07002086COMPLETED
Sponsor
Saglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital
Enrollment
22
Started
2025
Primary outcome
Activated Partial Thromboplastin Time(APTT)
Primary Gonarthrosis
DetectIon of Severe Sepsis In PATients With Neurological haemorrhagE (The DISSIPATE Study)
NCT04624945UNKNOWN
Sponsor
National University Hospital, Singapore
Enrollment
150
Started
2020
Primary outcome
To validate the use of APTT CWA and ICIS, as early sepsis markers for neurosurgical ICU patients suffering subarachnoid haemorrhage, traumatic brain injury and other intracranial haemorrhages.
SepsisHemorrhage Brain
Publication Trend
Research publications about aPTT over time
10totalTrack your bloodwork in PepStack
Log lab results, track trends and optimize your biomarkers over time.
Legal Disclaimer
This page is for informational and research purposes only. All information is based on published scientific literature and does not constitute medical advice, diagnosis, or treatment recommendations. Many substances listed may not be approved for human use and may be subject to drug regulation laws (e.g., AMG in Germany, FDA in the US). PepStack does not encourage the use of any substance on humans. Always consult a qualified healthcare professional before making any health-related decisions. Use of this information is entirely at your own risk. PepStack assumes no liability for the accuracy, completeness, or timeliness of the content provided. Full disclaimer